Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1507911

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1507911

mRNA Platform

PUBLISHED:
PAGES: 334 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global mRNA Platform Market to Reach US$120.2 Billion by 2030

The global market for mRNA Platform estimated at US$149.9 Billion in the year 2023, is expected to reach US$120.2 Billion by 2030, growing at a CAGR of -3.1% over the analysis period 2023-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.1% CAGR and reach US$96.5 Billion by the end of the analysis period. Growth in the Cancer Vaccine segment is estimated at 104.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.5 Billion While China is Forecast to Grow at -0.8% CAGR

The mRNA Platform market in the U.S. is estimated at US$67.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of -0.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -4.2% and -5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -3.8% CAGR.

Global mRNA Platform Market - Key Trends & Drivers Summarized

The mRNA platform has emerged as a groundbreaking innovation in the field of biotechnology and pharmaceuticals, revolutionizing the way vaccines and therapeutics are developed and deployed. mRNA, or messenger RNA, acts as a blueprint for protein synthesis within cells, and this technology harnesses that mechanism to instruct cells to produce specific proteins that can trigger an immune response or treat diseases. The success of mRNA-based COVID-19 vaccines, developed by companies like Moderna and Pfizer-BioNTech, has showcased the platform's potential for rapid and scalable vaccine production. Unlike traditional vaccines, which often require months or years to develop, mRNA vaccines can be designed and manufactured much more quickly, providing a crucial tool in responding to emerging infectious diseases.

Technological advancements have significantly enhanced the capabilities and applications of the mRNA platform. Innovations in lipid nanoparticle (LNP) delivery systems have improved the stability and efficiency of mRNA molecules, allowing for effective delivery into cells. This has broadened the potential applications of mRNA technology beyond vaccines to include treatments for cancer, genetic disorders, and other diseases. The flexibility of the mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine. Additionally, advancements in synthetic biology and bioinformatics have enabled more precise and efficient mRNA sequence design, optimizing the expression and effectiveness of the encoded proteins.

The growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Furthermore, substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges.

Select Competitors (Total 96 Featured) -

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Altogen Labs
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics
  • Aldevron
  • AKESOgen, Inc.
  • baseclick GmbH
  • chimeron bio
  • Acuitas Therapeutics
  • Accent Therapeutics
  • Accanis Biotech F&E GmbH & Co KG
  • Avectas
Show more
Product Code: MCP23108

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • mRNA Platform - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • mRNA - A CONCEPTUAL UNDERSTANDING
    • mRNA: A New Approach to Medicine
    • Long Wait & Scientific Breakthroughs
    • mRNA Vaccines - An Introduction
    • With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
    • mRNA: Making Cells Act as Vaccine Factory
    • mRNA Vaccines: Advantages
    • mRNA Vaccines: Cons
    • mRNA Vaccine Approvals
    • A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
    • Traditional Vs. mRNA Vaccines: Key Differences
    • Traditional Vs. mRNA Vaccines: The Development Process
    • How mRNA Vaccine Works & Earlier Testing Efforts
    • mRNA Vaccines: Safety Quotient
    • Other Notable Efforts Centered on mRNA Technology
    • Overcoming Challenges
    • As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
  • GLOBAL MARKET OVERVIEW
    • Global mRNA Vaccines Market on a Dynamic Growth Track
    • mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
    • The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
    • Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
    • RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
    • Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization
    • UK Clinches the First Position in the World to Approve Pfizer's Vaccine
    • After UK, US Gives Nod to Pfizer's Vaccine
    • EU Approves Pfizer's Vaccine
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna's mRNA Vaccine Bags Approval from US FDA
    • Moderna Kick-Starts Inoculation in the US
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
    • Recent Market Activity
  • COMPETITIVE SCENARIO
    • BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
    • List of BioNTech's mRNA Candidates in Clinical Trials for Cancer
    • Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All
    • Moderna's mRNA Prophylactic Vaccines
    • mRNA Cancer Vaccines
    • mRNA Intratumoral Immuno-Oncology
    • mRNA Systemic Secreted & Cell Surface Therapeutics
    • mRNA Systemic Intracellular Therapeutics
    • Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
    • mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
    • Noteworthy Startups Exploiting mRNA Technology
    • Providence Therapeutics
    • pHion Therapeutics
    • eTheRNA immunotherapies & 20Med Therapeutics
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
    • mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
    • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
    • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Increasing Healthcare Expenditure to Foster Market Growth
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Regulatory Landscape for mRNA Vaccines
    • Regulatory Pathway Dealing with mRNA Vaccines
    • mRNA Vaccine Patent Scenario
    • The Best Route of Administration for mRNA Vaccines
    • mRNA CANCER VACCINES
    • Introduction
    • Cancer Vaccines Vs. Immunotherapies
    • Clinical Trials of mRNA Encoding Immunostimulants
    • mRNA Vaccines Vs. DNA Vaccines
    • Clinical Trials of mRNA Encoding TAAs
    • mRNA Vaccines Vs. Other Vaccines
    • Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
    • mRNA Benefits Profile
    • mRNA Vaccines for Covid-19 Pave the Way
    • Challenges
    • Personalized mRNA Vaccine
    • Clinical Overview of mRNA Cancer Vaccines
    • mRNA encoding Immunostimulants
    • mRNA vaccine encoding tumor-associated antigens
    • mRNA vaccine encoding Neoantigen, personalized vaccine
    • mRNA Influenza Vaccines
    • Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
    • Vaccines Built on mRNA
    • Clinical Trials for mRNA Vaccines
    • mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
    • mRNA: A Next-Generation Vaccination Approach
    • Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
    • COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
    • mRNA Vaccines Vs. Other Flu Shots
    • mRNA Technology, H/N Spike Proteins & Clinical Trials
    • mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
    • Benefits & Limitations of mRNA Vaccines over Traditional Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Platform Market Analysis of Annual Sales in US$ Million for Years 2022 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • US FDA Gives Nod to Pfizer and Moderna's mRNA Vaccines
    • US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
    • Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
    • TABLE 10: USA Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 11: USA 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • CANADA
    • Vaccination Gathers Steam Across Canada
    • Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
    • COVID-19 Vaccine Deals in Canada
    • Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
    • Canada Grants Approval to Pfizer's COVID-19 Shot for Use in Children in 12-15 Years Age Group
    • TABLE 12: Canada Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 13: Canada 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • JAPAN
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • COVID-19 Vaccination Programs in Japan Move Forward at Snail's Pace
    • Reasons Responsible for Setback
    • Vaccine Timeline & Availability
    • Japan Demands for Vaccine-Related Data
    • People's Low Trust in Vaccines
    • Japan's Efforts to Develop Indigenous Vaccines
    • Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
    • Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
    • Japan Pushes Shipments of Pfizer's COVID-19 Shots to Vaccinate Elderly
    • TABLE 14: Japan Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Japan 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • CHINA
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • BioNTech's Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
    • TABLE 16: China Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: China 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • EUROPE
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
    • COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
    • EU Approves Pfizer's Vaccine
    • EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
    • European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • TABLE 18: Europe Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • FRANCE
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 22: France Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: France 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • GERMANY
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 24: Germany Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Germany 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • ITALY
    • Italy Plans to Produce mRNA Vaccines Domestically
    • TABLE 26: Italy Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Italy 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • UNITED KINGDOM
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • Market Analysis
    • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
    • Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
    • UK's Independent Vaccine Deals
    • TABLE 28: UK Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: UK 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of Europe 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • ASIA-PACIFIC
    • mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • INDIA
    • Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
  • AUSTRALIA
    • Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
  • NEW ZEALAND
    • New Zealand Acquires Ultra-Cold Freezers to Store Pfizer's COVID-19 Vaccine
    • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Asia-Pacific 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030
  • REST OF WORLD
  • THE MIDDLE EAST
  • BAHRAIN
    • Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer's Vaccine
  • AFRICA
  • SOUTH AFRICA
    • New Virus Variant in South Africa Creates a Challenge
    • Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
  • LATIN AMERICA
    • Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
  • BRAZIL
    • Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
  • MEXICO
    • Mexico's Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
    • TABLE 34: Rest of World Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Rest of World 7-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!